Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
DISCUSSION: Our study showed that there is a low treatment rate for onychomycosis, with treatment prescribed at only 20% of visits. Untreated onychomycosis might result in secondary infection, pain, and negative QoL impact.1 Although dermatologists are specialists in nail disease management, they saw only about 25% of onychomycosis visits. Future efforts should be directed towards promoting onychomycosis therapy, and educating both patients and referring physicians that dermatologists are primary resources for nail disorder treatment.J Drugs Dermatol. 2023;22(10):1040-1045 doi:10.36849/JDD.6770.PMID:37801531 | DOI:10.36849...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Gabrielle M Peck Alan B Fleischer Shari R Lipner Source Type: research
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7323.ABSTRACTRecently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medications can either be used continuously for several weeks at a lower dose or intermittently (pulsed) at a higher dose. Previous literature comparing pulse and continuous therapy has generated mixed results. Our study aims to compare the efficacy, in terms of clinical cure rate, of continuous vs pulse dose terbinafine regimens for toenail onychomyc...
Source: Journal of Drugs in Dermatology - October 6, 2023 Category: Dermatology Authors: Muhammad Amer Saleem Rohan R Shah Shawana Sharif Dip Rana Nadia Waqas Babar K Rao Source Type: research
Therapeutic treatment strategies for the management of onychomycosis: a patent perspective
. (Source: Expert Opinion on Therapeutic Patents)
Source: Expert Opinion on Therapeutic Patents - October 6, 2023 Category: Drugs & Pharmacology Authors: Snigdha Chakraborty SanshitaInderbir SinghChitkara College of Pharmacy, Chitkara University, Punjab, India Source Type: research
Fusariosis in cancer patients: 13 case series report and literature review
Biomedica. 2023 Aug 31;43(Sp. 1):41-56. doi: 10.7705/biomedica.6925.ABSTRACTThe fusariosis is an opportunistic mycosis caused by Fusarium spp. Its clinical presentation depends on the immunological status of the host, especially in patients with hematooncological diseases, whose manifestations vary from localized to invasive fungal infections. Skin or blood culture helps to guide combined antifungal treatment with amphotericin B and voriconazole. Here, we present 13 cases in a period of eleven years of patients with cancer who developed disseminated fusariosis and their outcomes, together with a review of the related liter...
Source: Biomedica : Revista del Instituto Nacional de Salud - September 18, 2023 Category: International Medicine & Public Health Authors: Sonia Isabel Cuervo-Maldonado Jos é Camilo Álvarez-Rodríguez Cristian Leonardo Cubides Juan Camilo Barrera Juan Diego Monta ñez-Abril Erika Paola Vergara-Vela Carlos Humberto Saavedra-Trujillo Mar ía José López-Mora Gloria Elena Mora-Figueroa Adria Source Type: research
